{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:23:41Z","timestamp":1782386621770,"version":"3.54.5"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001797","name":"Pharmaceutical Research and Manufacturers of America Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001797","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vascn.2023.107265","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T13:43:10Z","timestamp":1680010990000},"page":"107265","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute"],"prefix":"10.1016","volume":"121","author":[{"given":"Hugo M.","family":"Vargas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric I.","family":"Rossman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Wisialowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Pugsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Roche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary A.","family":"Gintant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Greiter-Wilke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert B.","family":"Kleiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek J.","family":"Leishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2023.107265_bb0005","series-title":"The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity","author":"Aitken","year":"2019"},{"key":"10.1016\/j.vascn.2023.107265_bb0010","series-title":"ICH S7A: Safety Pharmacology Studies for Human Pharmaceuticals","author":"Anonymous","year":"2000"},{"key":"10.1016\/j.vascn.2023.107265_bb0015","series-title":"ICH E14: The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non- antiarrhythmic drugs","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.vascn.2023.107265_bb0020","series-title":"ICH S7B: The nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals","author":"Anonymous","year":"2005"},{"key":"10.1016\/j.vascn.2023.107265_bb0025","series-title":"ICH E14 Guideline: The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs - Questions & Answers (R3)","author":"Anonymous","year":"2015"},{"key":"10.1016\/j.vascn.2023.107265_bb0030","series-title":"Final Concept Paper - ICH S7B and E14 Q&A","author":"Anonymous","year":"2018"},{"key":"10.1016\/j.vascn.2023.107265_bb0035","series-title":"ICH E14\/S7B Implementation Working Group Clinical and Nonclinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers","author":"Anonymous","year":"2022"},{"issue":"3","key":"10.1016\/j.vascn.2023.107265_bb0040","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/pst.454","article-title":"Review of the statistical analysis of the dog telemetry study","volume":"10","author":"Aylott","year":"2011","journal-title":"Pharmaceutical Statistics"},{"key":"10.1016\/j.vascn.2023.107265_bb0045","doi-asserted-by":"crossref","first-page":"107067","DOI":"10.1016\/j.vascn.2021.107067","article-title":"The in vivo QTc core assay: An evaluation of QTc variability, detection sensitivity and implications for the improvement of conscious dog and non-human primate telemetry studies","author":"Baublits","year":"2021","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.vascn.2014.05.004","article-title":"Translational PK\/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development","volume":"70","author":"Caruso","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107265_bb0055","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/qjmed\/hcm072","article-title":"Drug-induced QT prolongation and torsades de pointes: evaluation of a QT nomogram","volume":"100","author":"Chan","year":"2007","journal-title":"QJM: An International Journal of Medicine"},{"issue":"2","key":"10.1016\/j.vascn.2023.107265_bb0060","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vascn.2006.03.004","article-title":"Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation","volume":"54","author":"Chaves","year":"2006","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107265_bb0065","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.vascn.2007.04.002","article-title":"ILSI-HESI cardiovascular safety subcommittee dataset: an analysis of the statistical properties of QT interval and rate-corrected QT interval (QTc)","volume":"56","author":"Chiang","year":"2007","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"6","key":"10.1016\/j.vascn.2023.107265_bb0070","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1111\/cts.13103","article-title":"Evaluation of moxifloxacin in canine and non-human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration-QTc analysis","volume":"14","author":"Chui","year":"2021","journal-title":"Clinical and Translational Science"},{"issue":"3","key":"10.1016\/j.vascn.2023.107265_bib196","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ahj.2014.06.003","article-title":"Cardiac Safety Research Consortium: can the thorough QT\/QTc study be replaced by early QT assessment in routine clinical pharmacology studies? Scientific update and a research proposal for a path forward","volume":"168","author":"Darpo","year":"2014","journal-title":"Am Heart J"},{"issue":"4","key":"10.1016\/j.vascn.2023.107265_bib197","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/cpt.60","article-title":"Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase","volume":"97","author":"Darpo","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.vascn.2023.107265_bb0075","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: A scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation."},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11095-015-1760-9","article-title":"Assessment of interspecies differences in drug-induced QTc interval prolongation in cynomolgus monkeys, dogs and humans","volume":"33","author":"Dubois","year":"2016","journal-title":"Pharmaceutical Research"},{"key":"10.1016\/j.vascn.2023.107265_bb0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/cts.13454","article-title":"Evaluation of levocetirizine in beagle dog and cynomolgus monkey telemetry assays: Defining the no QTc effect profile by timepoint and concentration-QTc analysis","volume":"16","author":"Engwall","year":"2023","journal-title":"Clinical and Translational Science"},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0090","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.vascn.2013.04.008","article-title":"A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions","volume":"68","author":"Ewart","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107265_bib198","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicol Sci"},{"issue":"8","key":"10.1016\/j.vascn.2023.107265_bb0095","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1177\/0091270010381498","article-title":"Population pharmacokinetic and concentration\u2013QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies","volume":"51","author":"Florian","year":"2011","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.vascn.2023.107265_bb0100","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10928-017-9558-5","article-title":"Scientific white paper on concentration-QTc modeling","volume":"45","author":"Garnett","year":"2018","journal-title":"Journal of Pharmacokinetics and Pharmacodynamics"},{"key":"10.1016\/j.vascn.2023.107265_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vascn.2014.12.008","article-title":"Sensitivity of pharmacokinetic-pharmacodynamic analysis for detecting small magnitudes of QTc prolongation in preclinical safety testing","volume":"72","author":"Gotta","year":"2015","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2023.107265_bb0110","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cpt.2136","article-title":"Toward replacement of thorough QT studies","volume":"109","author":"van der Graaf","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.vascn.2013.05.004","article-title":"Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium","volume":"69","author":"Holzgrefe","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107265_bb0120","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1124\/pr.110.003723","article-title":"Drug-induced long QT syndrome","volume":"62","author":"Kannankeril","year":"2010","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.vascn.2023.107265_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.vascn.2019.106606","article-title":"Exposure-response analysis of drug-induced QT interval prolongation in telemetered monkeys for translational prediction to human","volume":"99","author":"Komatsu","year":"2019","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2023.107265_bb0130","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.vascn.2011.08.006","article-title":"Best practice in the conduct of key nonclinical cardiovascular assessments in drug development: current recommendations from the Safety Pharmacology Society","volume":"65","author":"Leishman","year":"2012","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0135","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.vascn.2013.04.006","article-title":"Intravenous solid tip ECG lead placement in telemetry implanted dogs: Part 2: High quality telemetry signals yield high sensitivity to drug-induced changes","volume":"68","author":"Mitchell","year":"2013","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"4","key":"10.1016\/j.vascn.2023.107265_bb0140","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bph.14101","article-title":"Can non-clinical repolarization assays predict the results of clinical thorough QT studies? Results from a research consortium","volume":"175","author":"Park","year":"2018","journal-title":"British Journal of Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0145","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/toxsci\/kfx125","article-title":"An analysis of the relationship between preclinical and clinical QT interval-related data","volume":"159","author":"Pollard","year":"2017","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2023.107265_bb0150","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1056\/NEJMra032426","article-title":"Drug-induced prolongation of the QT interval","volume":"350","author":"Roden","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.vascn.2023.107265_bb0155","doi-asserted-by":"crossref","unstructured":"Rossman, E.I. et al. (2023). Best practice considerations for nonclinical In Vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14\/S7B Q&As. J. Pharmacol. Toxicol. Methods (in submission).","DOI":"10.1016\/j.vascn.2023.107270"},{"issue":"3","key":"10.1016\/j.vascn.2023.107265_bb0160","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1177\/1091581811398963","article-title":"Cardiovascular function in nonclinical drug safety assessment: current issues and opportunities","volume":"30","author":"Sarazan","year":"2011","journal-title":"International Journal of Toxicology"},{"issue":"5","key":"10.1016\/j.vascn.2023.107265_bb0165","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1365-2125.2010.03741.x","article-title":"A safety grading scale to support dose escalation and define stopping rules for healthy subject first-entry-into-man studies: some points to consider from the French Club Phase I working group","volume":"70","author":"Sibille","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1016\/j.vascn.2023.107265_bb0170","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.vascn.2010.05.011","article-title":"Cardiovascular safety assessments in the conscious telemetered dog: utilization of super-intervals to enhance statistical power","volume":"62","author":"Sivarajah","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"3","key":"10.1016\/j.vascn.2023.107265_bib199","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40264-013-0016-z","article-title":"Dealing with global safety issues\u202f: was the response to QT-liability of non-cardiac drugs well coordinated?","volume":"36","author":"Stockbridge","year":"2013","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.vascn.2023.107265_bb0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/cpt.2137","article-title":"Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14\/S7B updates)","volume":"109","author":"Strauss","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.vascn.2023.107265_bb0180","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfac013","article-title":"The challenges of predicting drug-induced QTc prolongation in humans","volume":"187","author":"Valentin","year":"2022","journal-title":"Toxicological Sciences"},{"issue":"2","key":"10.1016\/j.vascn.2023.107265_bb0185","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/cpt.2029","article-title":"Time for a fully integrated nonclinical-clinical risk assessment to streamline QT prolongation liability determinations: A pharma industry perspective","volume":"109","author":"Vargas","year":"2021","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"3","key":"10.1016\/j.vascn.2023.107265_bb0190","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.vascn.2011.03.002","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effect of moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys","volume":"63","author":"Watson","year":"2011","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2023.107265_bb0195","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1136\/heart.89.11.1363","article-title":"Drug induced QT prolongation and torsades de pointes","volume":"89","author":"Yap","year":"2003","journal-title":"Heart"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871923000163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:05:11Z","timestamp":1761005111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871923000163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":43,"alternative-id":["S1056871923000163"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107265","relation":{},"ISSN":["1056-8719"],"issn-type":[{"value":"1056-8719","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2023.107265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Amgen, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"107265"}}